Invatec: Italy's Home-Grown Device Model

Invatec is the product of a father's natural technical skill and love of using technology to solve problems, passed on to his son and daughter. Initially based out of the Venturelli family's home, Invatec started by building custom products for interventional cardiologists in Germany and Italy, and then became an OEM supplier to larger companies. The company initially relied on the Venturellis' (father's and son's) engineering expertise to develop superior technology, while maintaining the responsiveness to physicians' demands that first brought the company to physicians' attention. The goal: to develop a broad-based interventional vascular products business globally under the Invatec name. Already selling products throughout Europe and Asia, the company is biding its time before entering the US market. Invatec's initial product lines include interventional cardiology catheters and balloons, an embolic protection system designed for carotid angioplasty, and a line of interventional peripheral vascular products. The company has also developed a radio frequency ablation system aimed at treating a variety of tumors. To this point, Invatec has largely operated beneath the radar screens of major cardiovascular device companies, which tend to see the company primarily as an OEM supplier. Invatec's efforts to launch a wide range of branded products will bring the company head-to-head with large companies in an already-consolidated market in which superior technology, while essential, is often not enough to carry the day on its own.

by Stephen Levin

Andrea Venturelli, founder and president of Brescia, Italy-based Invatec, is too young to recall when the film "The Graduate" was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.